title: [Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].
abstract: OBJECTIVE
  To investigate the efficacy and safety of goserelin plus anastrozole in advanced premenopausal breast cancer patients.
  
  
  METHODS
  We summarized a single-centre experience with goserelin plus anastrozole in 32 premenopausal women with metastatic breast cancer (MBC). All patients received goserelin 3.6 mg by subcutaneous injection every 4 weeks concurrently with anastrozole 1 mg daily. The median duration of treatment was 12 months.
  
  
  RESULTS
  No patient achieved complete remission (CR) (0%), 6 partial remissions (PR) (18.8%), 21 stable diseases (SD) (65.6%) and 5 progressive diseases (PD) (15.6%). Objective response rate (ORR) was achieved in 18.8% and clinical benefit (CR + PR + SD > 6 months) in 68.8%. The median progression-free survival (PFS) was 12 (2 - 57) months. One-year overall survival rate (OS) was 87.4% and two-year OS 66.9%. The OS of patients without visceral metastasis was significantly longer than that of patients with visceral metastasis (P = 0.04). Hot flushes and nausea were predominant toxicities.
  
  
  CONCLUSIONS
  The combination of goserelin and anastrozole appears to be an efficient and well-tolerated regimen in premenopausal MBC women.
authors.affiliation: Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
authors.forename: Shu-Yang
authors.initials: SY
authors.lastname: Yao
authors.forename: Bing-He
authors.initials: BH
authors.lastname: Xu
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.forename: Pin
authors.initials: P
authors.lastname: Zhang
authors.forename: Jia-Yu
authors.initials: JY
authors.lastname: Wang
authors.forename: Peng
authors.initials: P
authors.lastname: Yuan
authors.forename: Fei
authors.initials: F
authors.lastname: Ma
authors.forename: Rui-Gang
authors.initials: RG
authors.lastname: Cai
mesh_terms: D000328:Adult; D000077384:Anastrozole; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D017273:Goserelin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use; D017697:Premenopause; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D009570:Nitriles; D014230:Triazoles; D017273:Goserelin; D000077384:Anastrozole